Drugs / Bevacizumab-EU
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT04325698 Comparator | Jun 2020 → May 2021 | non-small cell lung carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT03329911 Comparator | Oct 2017 → Nov 2019 | non-small cell lung carcinoma | Bio-Thera Solutions | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bevacizumab-EU | “maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.” NCT03329911 ↗ |
| Known as | EU Avastin | “Drug: EU Avastin® 15 mg/kg IV infusions” NCT03329911 ↗ |
| Route | Intravenous | “EU Avastin® 15 mg/kg IV infusions” NCT03329911 ↗ |